SELECTBIO - 2D-to-3D Culture and Organoids 2020 Biographies

Home

Agenda

Keynote Speakers

Registration

Exhibition

Venue

Training Courses

Co-Located Conferences

Exploring the Utility of iPSC-derived 3D Cortical Spheroids in the Detection of CNS Toxicity

Thursday, 20 August 2020 at 10:00

Add to Calendar ▼2020-08-20 10:00:002020-08-20 11:00:00Europe/LondonExploring the Utility of iPSC-derived 3D Cortical Spheroids in the Detection of CNS Toxicity2D-to-3D Culture and Organoids 2020 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com

Drug-induced Central Nervous System (CNS) toxicity is a common safety attrition for project failure during discovery and development phases due to low concordance rates between animal models and human, absence of clear biomarkers, and a lack of predictive assays. To address the challenge, we validated a high throughput human iPSC-derived 3D microBrain model with a diverse set of pharmaceuticals. We measured drug-induced changes in neuronal viability and Ca channel function. MicroBrain exposure and analyses were rooted in therapeutic exposure to predict clinical drug-induced seizures and/or neurodegeneration. We found that this high throughput model has very low false positive rate in the prediction of drug-induced neurotoxicity. This assay has the potential to be used as a predictive assay to detect neurotoxicity hazard identification in early drug discovery.

Qin Wang, Scientist, Drug Safety Research & Evaluation, Takeda Pharmaceuticals, Inc.

Dr. Wang received a Ph.D in Molecular Toxicology and Master degree in Biostatistics from the University of Cincinnati. After finished one year’s postdoctoral training in computational toxicity, Dr. Wang moved to Drug Safety Research & Evaluation of Takeda Pharmaceuticals in early 2017, where she designs, develops and implements custom microtissue models to improve the safety profile of drug discovery portfolio, with a focus on bone marrow and CNS toxicities. Dr. Wang uses in vitro de-risking strategies to aid in the selection and optimization of large and small molecular therapeutics. Research interests include new modalities-caused CNS toxicities, and application of iPSC-derived 3D models to de-risk toxicities in early drug discovery.